Company intelligence

LENZ

LENZ Therapeutics, Inc. · NASDAQ · Healthcare

Price$4.79+2.57% · +$0.12

Market cap150.19MEquity value

P / E-1.2Trailing ratio

Volume361.97KLatest session

Market data

LENZ price chart

TradingView

Related signals

1 min delayed

Browse public LENZ signals with their source context and measured market impact. Open any signal for its permanent analysis page.

LENZJan 30, 2026-0.92% since signal

New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug

The FDA approved Tenpoint Therapeutics' Yuvezzi, the first dual-agent eyedrop for presbyopia. This development potentially intensifies competition in the ophthalmic solutions market, impacting LENZ's market share and profitability.

View signal analysis

LENZOct 28, 2024+0.50% since signal

LENZ Therapeutics' Investigational Drug For Age-Related Blindness Aces Pivotal China Trial, Analyst Says Data Readout May Strengthen Position For Ex-U.S. Partnerships

LNZ100 achieved primary and key secondary endpoints in Phase 3 trial. 84% and 69% improved vision significantly; well-tolerated with no serious adverse events. Results enhance confidence for real-world performance upon FDA approval. FDA target action date is August 8, 2025 for LNZ100. Positive trial results could strengthen partnership discussions for Lenz.

View signal analysis

LENZApr 3, 2024

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

- Lenz Therapeutics' near vision drugs successful in late-stage study, causing stock surge. Price Impact Rating: Very Bullish Impact Horizon Rating: Short-Term Type: Corporate Developments

View signal analysis

Research